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The Jeryl Lynn (JL) vaccine against mumps virus (MuV) contains two components, MuV
JL5 and
MuV
JL2, which differ by over 400 nt. Due to the occurrence of bias in the direction of mutation,
these differences and those found in nucleotide sequences of different isolates of the minor
component in the vaccine (MuV
JL2) might be due to the effect of ADAR-like deaminases on MuV
grown in tissue-cultured cells. A molecular clone of MuV
JL2 (pMuV
JL2) and MuV
JL2-specific helper
plasmids were constructed in order to investigate molecular interactions between MuV
JL5 and
MuV
JL2, to augment the existing molecular clone of MuV
JL5 (pMuV
JL5) and MuV
JL5-specific helper
plasmids. Genome and mRNA termini of MuV
JL2 were characterized, and an unusual oligo-G
insertion transcriptional editing event was detected near the F mRNA polyadenylation site of
MuV
JL2, but not of MuV
JL5. Genes encoding glycoproteins of rMuV
JL2 and rMuV
JL5 have been
exchanged to characterize the oligo-G insertion, which associated with the specific sequence of
the F gene of MuV
JL2 and not with any other genes or the RNA-dependent RNA polymerase of
strain MuV
JL2. The results indicate that a single G-to-A sequence change obliterates the co-
transcriptional editing of the F mRNA and that this oligo-G insertion does not affect the growth of
the virus.
INTRODUCTION
The Jeryl Lynn (JL) mumps virus (MuV) vaccine contains
two different component strains, MuV
JL5 and MuV
JL2, that
differ considerably in their nucleotide sequences (Amexis
et al., 2002). The mechanisms that generated the two
variants are unclear. MuV belongs to the genus Rubulavirus
of the subfamily Paramyxovirinae. The inner core consists of
the non-segmented negative-strand viral RNA (length,
15384 nt) associated with the nucleocapsid (N) protein,
lesser amounts of the polymerase associated phospho- (P)
protein and small amounts of the large (L) RNA-dependent
RNA polymerase (RdRp) protein. In the virion, the
ribonucleoprotein (RNP) is surrounded by a host-derived
membrane, which is spanned by two glycoproteins: the
haemagglutinin–neuraminidase (HN) and fusion (F) pro-
teins. On the inner face of the membrane is a membrane or
matrix (M) protein that interacts with the cytoplasmic tails
of the HN and F proteins and with the RNP. The virus also
expresses three non-structural proteins. Two are derived
from the second transcription unit, which encodes the non-
structural V protein directly and, after co-transcriptional
editing of the transcripts, gives rise to two other proteins, P
and W. The W protein is a second non-structural protein
consisting of a truncated version of V, which substitutes a
short peptide of unknown function, encoded by the third
potential reading frame, for the cysteine-rich tail that is
characteristic of the V proteins of all members of the
Paramyxovirinae. The third non-structural protein is a small
hydrophobic (SH) protein that is derived from a transcrip-
tion unit between those encoding the F and HN proteins
(Elliott et al., 1989; Elango et al., 1989). Although some
aspects of the replication of MuV have been studied at the
molecular level, others have been inferred only by analogy to
other members of the Paramyxovirinae. For example, the
genome and 59 transcriptional termini of MuV have been
generally inferred from sequence comparisons rather than
determined directly. The mRNA 39 termini have been better
characterized by sequencing cDNA clones generated by
oligo-dT priming on MuV mRNA (Elango et al., 1988).
Furthermore, polyadenylation and polymerase slippage at
the 39 end of the genes and at the editing site have not been
subjected to rigorous analysis, and direct proof of the
inferred sequence determinants is lacking. The development
ofreverse-geneticssystems(Amexisetal.,2002;Lemonetal.,
2007) now allows many of the basic parameters of MuV
replication to be studied in detail.
The GenBank/EMBL/DDBJ accession number for the final consensus
full-length sequence of Jeryl Lynn mumps virus sub-strain JL2 genomic
RNA is FN431985.
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a single clinical isolate (Afzal et al., 1993), which was
converted into a live-attenuated vaccine by passage of virus
in non-human host cells. The complete nucleotide
sequences of MuV
JL5 and MuV
JL2 have been reported
(Clarke et al., 2000; Amexis et al., 2002) and show 414
nucleotide changes, resulting in 87 amino acid changes,
between Muv
JL5 and MuV
JL2. This level of variation is at
the same level as differences between genotypes of MuV.
There are biological differences between MuV
JL5 and
MuV
JL2. For example, MuV
JL2 grows better in embryo-
nated eggs than MuV
JL5, but immunological differences
have not been reported (Amexis et al., 2002). Both MuV
JL5
and MuV
JL2 are non-neurovirulent in the rat neuroviru-
lence test (Rubin et al., 1999, 2000, 2003). Molecular
differences other than the nucleotide sequences have not
been investigated extensively.
METHODS
Virus strains and cell-culture procedures. A549 and Vero cells
were grown in Dulbecco’s modified Eagle’s medium (DMEM;
Invitrogen) supplemented with 10% (v/v) fetal calf serum (FCS;
Invitrogen). MuV strains MuV
JL5, MuV
JL2 and MuV
KH were obtained
from Dr D. Clarke (Wyeth-Lederle Vaccines, Pearl River, NY 10965,
USA), Dr M. Afzal (National Institute for Biological Standards and
Control, Potters Bar, London, UK) and Dr S. A. Rubin (Center for
Biologics Evaluation and Research, Food and Drug Administration,
Bethesda, MD, USA), respectively. Modified vaccinia virus Ankara
(MVA-T7) was grown as described previously (Duprex et al., 1999).
For virus growth curves, Vero cells were grown in 75 cm
2 bottles and
infected at 50% confluence at an m.o.i. of 0.01, and maintained in
10 ml DMEM/10% (v/v) FCS. Virus titres were determined by
TCID50 for both cell-associated and supernatant virus. Cells were
scraped at the given time points into the growth medium and
supernatant was separated by 5 min centrifugation at 3000 r.p.m.
(1200 g) (with pelleted cell-associated material resuspended in 10 ml
fresh DMEM/10% FCS). TCID50 titres were determined in triplicate
by a 50% end-point dilution assay in 96-well trays of Vero cells, as
described previously (Duprex et al., 1999).
Bacterial strains and plasmids. Escherichia coli strain DH5aIQ was
used for routine transformations; highly competent E. coli strains XL
blue and TOP10 were obtained from Stratagene and Invitrogen,
respectively, and used where fewer transformants were expected. The
full-length MuV clone pMuVFL encoding MuV
JL5, helper plasmids
encoding MuV
JL5 N, P and L proteins and pMuVDICAT were
obtained from Dr D. Clarke (Wyeth-Lederle Vaccines, Pearl River,
NY 10965, USA). The cytomegalovirus (CMV) promoter-based
expression plasmid pCG (Cathomen et al., 1995) was used as the
basis for construction of MuV
JL2-specific helper plasmids pCG-N
JL2,
pCG-P
JL2 and pCG-L
JL2.
Reagents. Oligonucleotides were obtained from Qiagen. TRIzol
reagent was from Invitrogen. Restriction enzymes, reverse transcrip-
tase SuperScript III, high-fidelity Taq DNA polymerase, Pfu
polymerase, Phusion DNA polymerase, Klenow fragment of DNA
polymerase, exonuclease III and DNA ligase were obtained from New
England Biolabs (NEB) or Invitrogen and used according to the
manufacturers’ instructions.
Recombinant DNA manipulations. PCR products corresponding
to MuV genes were generated with unique terminal restriction-
enzyme sites and cloned into suitable intermediate vectors to generate
two vectors containing approximately half of the MuV
JL2 genome.
One half comprised the leader to the HN gene and was constructed in
pUC18 by sequential ligations of genes from Muv
JL2. The other half,
comprising the L gene, was amplified in two overlapping segments
and cloned sequentially into a modified form of the pBluescript-
derived pMuV
JL5 by deletion from N to HN, i.e. from an SphI site
near the start of the N gene to an NheI site near the end of the HN
gene, thus replacing the L gene of MuV
JL5 with that of MuV
JL2. In the
final stage, the leader to HN region of MuV
JL2 from the pUC18-based
intermediate was cloned into the pBluescript/MuV
JL2 L gene
intermediate to generate a full-length clone of strain MuV
JL2.
Details of oligonucleotides, enzymes etc. can be supplied on request.
The initial full-length clone of MuV
JL2 was modified by rounds of in
vitro mutagenesis of subgenomic clones, which were transferred to the
full-length clone to insert further restriction sites at intergenic
locations or to eliminate them elsewhere. Recombinant DNA
operations were initially performed by standard RT-PCR, restrictions
and ligations according to the manufacturers’ protocols, but a simple
form of ligation-independent cloning (Aslanidis & de Jong, 1990; Li &
Evans, 1997) was used for most procedures after the generation of the
first full-length clone of MuV
JL2. In brief, 1–200 ng restricted vector
and 1–200 ng desalted PCR product (generated using oligonucleotides
with termini homologous with vector and a DNA polymerase that
generates blunt-ended PCR products) for insert were incubated for
10 min at 37 uC in a final volume of 10 ml of NEB buffer 1 (or the
buffer with the lowest ionic strength consistent with digestion of
vector) with 10 units exonuclease III. Next 2 ml 1 M NaCl was added
and exonuclease III was heat-inactivated at 75 uC for 15 min. The
reaction mixture was cooled slowly from approximately 55 to 37 uCi n
about 1.5 h in an insulated beaker of water and transformed into
competent E. coli. The final full-length clone of MuV
JL2 was designated
pMuV
JL2 and has restriction sites with blunt ends or 59 restriction
overhangs engineered in all intergenic positions, internal to all viral
genes except SH and spaced evenly throughout L, because exonuclease
III is reliable for 39–59 digestion of such restriction sites. The clone of
the HN gene of MuV
JL2 to the pMuV
JL5 vector involved cloning to an
SgfI site with a 39 overhang on which exonuclease III is inactive.
Klenow fragment of DNA polymerase, which has both 59–39 and 39–59
exonuclease activities, was used instead of exonuclease III for digestion
of DNA during this procedure. In vitro mutagenesis was also
performed by exonuclease III digestion of overlapping blunt-ended
PCR termini generated with mutagenic oligonucleotides followed by
annealing as above. Smaller plasmids (i.e. any gene except L in the
initial small plasmid cloning vectors) could be mutated from a single
PCR product, but longer DNAs (e.g. of the L gene half-genome
clones) were generated as two overlapping pieces from the site of
mutation to a site in the ampicillin-resistance gene of the vector.
Determination of MuV RNA termini by rapid amplification of
cDNA ends (RACE). The 59 termini of all MuV mRNAs and both
genomic termini were determined by RACE after PCR using G-tailed
cDNAs with a negative-sense gene-specific primer located close to the
gene start for each mRNA (that for N generated two termini – that of
the N mRNA and that of the antigenome; that for HN generated
termini for both HN and SH) or a positive-sense primer located close
to the end of the L gene for the 59 terminus of the genome, and a
common oligo-dC tailed primer as described previously (Barr et al.,
1994). The 39 termini of F gene mRNAs were determined in similar
fashion after PCR using oligo-dT-primed cDNAs with a positive-
sense primer located near the end of the F gene and an oligo-dT-tailed
primer. Nucleotide sequences of all RNA termini were determined
directly from the PCR products.
Rescue of recombinant viruses from cDNA clones. Initial rescue
by transfection of full-length and helper plasmids to MVA-T7-
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2000), was used for rescue of all recombinant viruses. When MuV
JL2
helper plasmids were used, 2 mg pCG-N
JL2,1mg pCG-P
JL2 and 0.1 mg
pCG-L
JL2 substituted for the MuV
JL5 analogues. Rescued recombin-
ant viruses were verified by nucleotide sequence analysis of PCR-
amplified viral genes using amplification without reverse transcrip-
tion as a negative control.
RESULTS
Sequence variation between MuV
JL2 and MuV
JL5 is
extensive
Numerous clone-to-clone variations were detected when
the PCR products corresponding to MuV
JL2 genes were
sequenced and, in most instances, it was difficult to
determine whether these were generated in the RT-PCR or
whether they reflect genuine quasi-species variations in the
virus population. The final consensus full-length sequence
is available under GenBank accession no. FN431985. The
numbers of differences between our consensus MuV
JL2
sequence, the published consensus MuV
JL2 sequence and
the consensus sequence of strain MuV
JL5 (Clarke et al.,
2000; Lemon et al., 2007) are shown in Table 1. Three
clusters of variations between our MuV
JL2 sequences and
those published were present and may be the result of
hypermutation events, as they were all of the form where T
(in the cDNA sequence) in one sequence was substituted
by C in the other. One cluster is in the 39 non-coding
region of the L gene (nt 15254–15317) where there are six
changes in 64 bases, of which five are T in the published
MuV
JL2, but are C in our sequence – MuV
JL5 has T at all
these positions. The second region is in the P gene
(nt 2217–2323) where there are seven changes in 107 bases,
of which six are C in the published MuV
JL2, but are T in
our sequence – MuV
JL5 has T at these positions. The third
region (nt 2459–2582) is also in the P gene (and was
variable within our own series of clones) where there are
three changes in 126 bases, all of which are T in the
published MuV
JL2 sequence and in one of our cDNA
clones, but are C in two other cDNA clones – MuV
JL5 has T
at these positions. These three clusters contain 16 changes
in 297 bases, a divergence of 5.4%; this is very high
compared with the remainder of these full-length
sequences, where there are 35 changes in 14987 nt, a
divergence of 0.2%, and thus contributes substantially to
the overall genomic sum of 51 changes in 15384 bases, a
divergence of 0.3%. A further potential biased mutation
event that may have occurred during passage of MuV
JL2
and MuV
JL5 is located in the 39 non-coding region of the N
gene (nt 1804–1870) where there are nine changes between
MuV
JL5 and both MuV
JL2 sequences, of which eight are T
in both of the MuV
JL2 sequences, but C in MuV
JL5. A tenth
change (nt 1820) in this region is present only in our
MuV
JL2 sequence, where T replaces C of the other two
sequences.
Transcription of the MuV
JL2 genome
Direct determination of the MuV genome and mRNA 59
termini by PCR and sequencing was carried out in parallel
with PCR and sequencing during construction of pMuV
JL2.
This is important, as the current basis for the MuV genome
annotation is founded primarily on inference. The 59
termini of all mRNAs and the genomic termini of MuV
JL2
were determined precisely by RACE (Fig. 1). All termini
were found to be as suggested previously on the basis of
sequence homology and conservation (Elango et al., 1988;
Okazaki et al., 1992). A non-templated base [predomi-
nantly seen as G in the positive sense, as found previously
(Barr et al., 1994; Collins et al., 1984)] was present between
the mRNA 59 termini and the cDNA tail for all mRNA
starts, and corresponds to the mRNA cap structure, as no
such nucleotide is present in either genome-terminal
sequence.
Table 1. Nucleotide and amino acid differences between MuV
JL5 and MuV
JL2
Values are shown as number of changes (percentage difference). MuV
JL2 db is the sequence from Amexis et al. (2002);
MuV
JL2 cons is our consensus sequence.
Sequence Length (aa) Comparison
MuV
JL5/MuV
JL2 db MuV
JL5/MuV
JL2 cons MuV
JL2 db/MuV
JL2 cons
Nucleotide – 414 (2.7) 421 (2.7) 51 (0.3)
Protein
N 550 7 (1.3) 6 (1.1) 1 (0.2)
P 392 12 (3.0) 10 (2.6) 6 (1.5)
V 225 7 (3.1) 4 (1.8) 3 (1.3)
M 376 5 (1.3) 7 (1.9) 4 (1.1)
F 539 13 (2.4) 13 (2.4) 2 (0.3)
SH 58 6 (10.3) 5 (8.6) 1 (1.7)
HN 583 14 (2.4) 16 (2.7) 2 (0.3)
L 2262 13 (0.6) 10 (0.4) 3 (0.1)
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termini and polyadenylation signals of all genes except L
were identified directly in the SBL1 strain of MuV
(MuV
SBL) and located in tracts of six and seven adenosine
residues (positive-sense sequence). We directed our
attention to the 39 end of the F gene of MuV
JL2 where
there are two such tracts separated by only seven
intervening bases, one of six and one of seven adenosine
residues, which are both rather similar to potential
polyadenylation-site motifs. There is also sequence diver-
gence between strains MuV
JL2 and MuV
JL5 with three
changes out of eight bases in part of the region comprising
the two polyadenylation motifs (Fig. 2). In addition, the
Enders strain of MuV (MuV
Enders) expresses only F–SH
read-through transcripts and has an A-to-G mutation in
the region comprising the seven-adenosine tract of the
other MuV strains (Takeuchi et al., 1991). We mapped the
39 end of the F mRNA by RACE to determine which
polyadenylation motif (or neither, or both) might be used
during mRNA synthesis for MuV
JL2. All polyadenylation of
the F gene of MuV
JL2 occurred at the second motif (Fig. 3)
in the seven-adenosine tract at the end of the F gene, which
is also used for polyadenylation of the MuV
JL5 F mRNA.
An oligo-G insertion transcriptional editing event
in the 3§ UTR of the F gene of MuV
JL2
Although the first of the two potential polyadenylation
signals did not appear to be used, it did allow slippage of
the RdRp to occur as, surprisingly, a small number of
additional G residues were inserted into the F mRNA in
MuV
JL2-infected cells at the GG sequence after the first
motif (Fig. 3b). This process resembles slippage of the viral
polymerase at the P/V editing site in the P gene. The F gene
Fig. 1. Location of MuV
JL2 genome termini and mRNA 59 termini. Sequence chromatograms that identify MuV
JL2 genome
termini and mRNA 59 termini. In (a–h), the orientation of the chromatograms has been reversed so that all sequences can be
read in the standard positive direction. Ten bases of tail/cap artefact and 10 bases of viral sequence are shown for each. (a, i)
Genome 59 and 39 termini; (b–h) 59 termini of the N, P/V, M, F, SH, HN and L mRNAs, respectively. Pairs of sequences (a) and
(b) or (f) and (g) were taken from the same electrochromatograms. Arrowheads in (b–h) indicate the base inserted
complementary to the mRNA methylated guanosine cap structure – this is predominantly C in the cDNA copy and thus appears
as G in this orientation. The peak signals in the M mRNA start (d) were higher than optimal, generating artefact peaks under the
tail. The F mRNA start (e) also contains a minor signal from the M–F gene junction. The HN mRNA start (g) contains a signal
from an abundant SH–HN transcript of approximately equal intensity to the tail itself (Afzal et al., 1990).
Fig. 2. Potential polyadenylation motifs at the
39 termini of MuV F gene transcripts. The
sequences of the 39-terminal regions (positive
strand) of the F mRNAs from MuV
SBL, MuV
JL2,
MuV
JL5, MuV
KH and MuV
Enders are aligned,
with differences from MuV
JL5 boxed. The two
polyadenosine tracts at the end of the F gene
of MuV
JL2 are indicated by bars beneath the
sequences.
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KH) is similar to MuV
JL2
in that it contains tracts of both six and seven adenosine
residues at the end of the F gene (Tecle et al., 2000; Lemon
et al., 2007), but is similar to MuV
JL5 in that it contains GA
instead of GG between the two tracts (Fig. 2). When the 39-
terminal region of the MuV
KH F mRNA was sequenced,
there was no oligo-G insertion, which suggests that the
presence of the second G of the GG between the two
adenosine tracts is necessary for the oligo-G insertion event
to occur (Fig. 3e).
Development of a reverse-genetics system for
MuV
JL2
It became clear that not only was the sequence of our
MuV
JL2 component (Afzal et al., 1993) (received as an early
passage after isolation and plaque purification of the
MuV
JL5 and MuV
JL2) different from the MuV
JL5 sequence,
but also that the level of variation between our MuV
JL2
sequence and the published MuV
JL2 sequence was signific-
ant (51 nt). In order to facilitate further molecular studies,
to investigate the phenotypes of recombinants between
MuV
JL2 and MuV
JL5, we developed a reverse-genetics
system for MuV
JL2 that complements the existing system
for MuV
JL5 (Lemon et al., 2007; Clarke et al., 2000). The
plasmid pMuV
MPBS (Lemon et al., 2007) derived from
MuV
JL5 is hereafter referred to as pMuV
JL5 for clear
differentiation from pMuV
JL2. Plasmid pMuV
JL2 was
constructed by using the pBluescript plasmid, T7 promoter
and hepatitis delta ribozyme from the pMuV
JL5 system
(Clarke et al., 2000) and engineered to fit the consensus
sequence described above except (i) where restriction sites
were introduced or removed that would not alter the viral
proteins, but would allow easy exchange of genes between
MuV
JL5, MuV
JL2 and other MuV strains, and (ii) where a
potential minor mutation event was detected in the P gene
(three nucleotides, 2459, 2534 and 2582, are all T in the
full-length plasmid, but C in most of the P gene clones),
because both MuV
JL5 and the previously published MuV
JL2
sequence have T at these three positions. Restriction-
enzyme sites at intergenic locations between genes
encoding the envelope proteins of pMuV
JL5 have been
incorporated during the construction of pMuV
JL2 (the
unique restriction site between F and SH is, however, AvrII
in pMuV
JL2 rather than BmgBI as in pMuV
JL5, because
pMuV
JL2 has an additional BmgBI site in the L gene and
there are both SgfI and SapI unique restriction sites
between SH and HN in pMuV
JL2). Additional unique
restriction-enzyme sites have been generated between all
other genes and internal to all viral genes (except for that of
SH) and spaced fairly evenly throughout the L gene to
facilitate molecular studies (Fig. 4).
Although helper plasmids appear to be interchangeable in
the rescue systems for all molecular clones tested, from our
direct experience, it appeared advisable to use homologous
plasmids in order to avoid inter-strain recombination
events driven by vaccinia virus (data not shown).
Therefore, MuV
JL2-specific helper plasmids encoding the
N, P and L genes (pCG-N
JL2, pCG-P
JL2 and pCG-L
JL2,
Fig. 3. Oligo-G insertion event at the 39
terminus of the F mRNA in MuV
JL2.
Sequence chromatograms from strains
MuV
JL2 (a, b), MuV
JL5 (c, d) and MuV
KH (e)
are shown. (a) and (c) show the virion RNA
sequence of the F–SH intergenic region
determined from PCR products generated
with F- and SH-specific primers, where ran-
dom primers were used to prime cDNA
synthesis on virion RNA extracted from cen-
trifuged growth medium (i.e. supernatants)
from infected cells (primarily genome/anti-
genome RNA). (b), (d) and (e) show the 39-
terminal region of the F mRNA determined
from PCR products generated with F gene-
and poly(A)-specific primers, where oligo-dT
was used to prime cDNA synthesis on RNA
extracted from infected cells (primarily mRNA).
The oligo-G insertion event in (b) is indicated
by a black bar and polyadenylation in (b), (d)
and (e) by dotted arrows.
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driven vector pCG and these were used successfully in the
rescue of the pMuV
JL2. A mumps minigenome construct
that encodes enhanced green fluorescent protein (EGFP)
(pMuV
EGFP) has been constructed by replacing the
chloramphenicol acetyltransferase open reading frame of
pMuVDICAT (Clarke et al., 2000) with that for EGFP.
pMuV
EGFP has been rescued with both the MuV
JL2 and
MuV
JL5 sets of helper plasmids (data not shown). A
recombinant virus, rMuV
JL2, was rescued successfully from
plasmid pMuV
JL2. The growth of this virus was very similar
to that of the original plaque-purified virus MuV
JL2,
confirming that the synonymous genetic alterations that we
have made do not affect virus growth dynamics in Vero
cells (Fig. 5).
Construction of chimaeric rMuV
JL2 and rMuV
JL5
viruses to characterize the oligo-G insertion
at the end of the F mRNA of MuV
JL2
In order to determine whether the oligo-G insertion at the end
of the F mRNA of MuV
JL2 was determined by the nucleotide
sequence at the end of the MuV
JL2 F gene, by characteristics of
the viral polymerase of strain MuV
JL2 or by other determi-
nants in the genome of this MuV strain, the F gene of MuV
JL2
was transferred into MuV
JL5 and the F gene of MuV
JL5 into
MuV
JL2 by using the unique between-gene restriction sites that
are present in the plasmids. The corresponding viruses were
rescuedandthe39termini ofthe F mRNAswere characterized.
The recombinant rMuV
JL5 (F
JL2)d i s p l a y e dt h es a m eo l i g o - G
insertion as the MuV
JL2 F gene, and the rMuV
JL2 (F
JL5)
displayed no oligo-G insertion (Fig. 6). This indicates that the
oligo-G insertion was associated with the F gene sequence of
MuV
JL2 rather than being a characteristic of the viral
polymerase of strain MuV
JL2.
DISCUSSION
The origin of the sequence variation between the MuV
JL5
and MuV
JL2 components of the live-attenuated JL vaccine
Fig. 4. Molecular clone of MuV
JL2, indicating gene boundaries and restriction sites in pMuV
JL2. The bar shows the antigenome
of pMuV
JL2 and the locations of viral genes (not to scale). Arrows beneath the bar indicate the location of unique restriction sites
suitable for ligation-independent cloning using exonuclease III in pMuV
JL2. The vector sequence flanking the antigenome
contains a NotI site upstream of a T7 RNA polymerase promoter located 59 to the antigenome (i.e. to the left of N) and a KasI
site downstream of the antigenome 39 terminus (i.e. to the right of L) which is internal to the hepatitis delta ribozyme (these
restriction sites are shown in bold). (a) Restriction sites present in the consensus MuV
JL2 sequence – these were either already
unique in the consensus MuV
JL2 sequence or made unique by mutagenesis of sites at other locations in the MuV genome or the
plasmid vector. (b) Restriction sites introduced into the final clone by in vitro mutagenesis. Additional SmaI, AvrII, BsrGI and
XhoI restriction sites in the MuV
JL2 sequence (c) were removed by in vitro mutagenesis. A SapI site and two FspI sites were
removed from the vector sequence by in vitro mutagenesis or deletion to render sites in the MuV
JL2 sequence unique in the final
clone. Restriction-enzyme names are abbreviated for clarity. Details of their position in the MuV
JL2 sequence are available on
request. The asterisks indicate that these sites are unique in the plasmid DNA which is methylated, as there are two sites at
11408–11413 and 11608–11613 that are also cleavable with StuI and NruI, respectively, in unmethylated plasmid DNA.
Fig. 5. Growth curves of MuV
JL2 and rMuV
JL2. Supernatant (a)
and cell-associated (b) titres of samples harvested from infected
Vero cells at days 0–7 post-infection were determined by TCID50.
The stock plaque-purified MuV
JL2 supplied by Dr M. Afzal and the
final recombinant virus rescued from cDNA are shown as MuV
JL2
(&) and rMuV
JL2 (m), respectively. Error bars represent SD.
P. Chambers, B. K. Rima and W. P. Duprex
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isolate. These, in general, display a consensus sequence
with little detectable variation and, hence, it is likely that
some part of the variation between the two vaccine
components has been generated after the original isolation
and during the attenuation process. Selection of a more
neurovirulent variant of MuV
JL5 has been shown to be
associated with only three amino acid changes and relative
sequence stability of this virus (Rubin et al., 2003). The
substantial sequence differences between MuV
JL2 deter-
mined in different laboratories suggest that cytosine or
adenine deamination events may play a significant role in
the generation of diversity between the MuV
JL strains. It is
to be noted that Amexis et al. (2002) did not succeed in
propagating a MuV
JL2 virus, but that the sequence was
derived from sequence variations found in the vaccine.
Though it was inferred to be preferably propagated in
chicken embryo cells, their MuV
JL2 could not be propa-
gated on Vero cells and, hence, they suggested that MuV
JL2
was a not completely defective satellite virus. Our sequence
is derived from a plaque-purified Vero cell-propagated
MuV
JL2 isolate. Amexis et al. (2002) posed the question of
whether the MuV
JL2 sequence is a passenger virus of
MuV
JL5. The fact that we were able to set up a rescue
system based on the MuV
JL2 consensus sequence with its
own helper plasmids indicates that the vaccine is a mixture
of two independently replicating viruses. In fact, titres of
MuV
JL2 are routinely at least 1 log10 higher than those of
MuV
JL5 in Vero cells in our hands. This, and the number
and location of unique restriction-enzyme sites that did not
affect the viral protein sequences and the even spacing of
unique restriction sites in pMuV
JL2, should be of benefit in
future molecular studies of MuV and may prove to be
advantageous in the use of the MuV
JL2 rescue system.
The prevalence of CAU and UAC mutations and the
identification of the localized nature of the biased
hypermutation indicate that deamination reactions by
ADAR- or APOBEC-like enzymes may play a role in the
generation of the sequence variation between MuV
JL5 and
MuV
JL2, although this remains to be formally proven. In
most cases, biased hypermutation events lead to functional
impairment of the affected region of the viral genome, for
example in measles virus sequences obtained from cases of
subacute sclerosing panencephalitis (Cattaneo et al., 1988).
Interestingly, loss of function does not seem to be the case
here. The potential events in L and N genes are located in
the 39 non-coding regions. One potential event in the P
gene affects an area with low sequence similarity at the N-
terminal part of the V/P protein. The other event present in
most but not all of our MuV
JL2 P clones affects the V but
not the P protein and this may alter the interferon
sensitivity of the MuV
JL2 virus. Biased hypermutation has
been described for several other viruses (Bass, 2002) and
may reflect the deaminating activity of the ADAR or
APOBEC enzymes themselves (Bass, 2002; Bishop et al.,
2004) or their ability to bind to RNA (Nie et al., 2007).
This study shows for the first time, to our knowledge, the
MuV genome and 59 termini of the mRNAs and that these
had been predicted correctly from the conservation of
motifs, and demonstrates the capped nature of these
mRNAs in contrast to the uncapped terminal sequences of
the genome. Earlier studies were not able to determine the
precise mRNA start sites, although polyadenylation signals
had been identified correctly (Elango et al., 1988). The
polyadenylation signal at the end of the F gene of MuV
JL2
required clarification because of the sequence variation
amongst strains of MuV at this point. Read-through from
the F to SH transcription units is found in MuV
Enders
Fig. 6. 39-Terminal sequences of F genes and
transcripts of rMuV
JL2(F
JL5) and rMuV
JL5(F
JL2).
(a, b) Sequence from rMuV
JL2(F
JL5); (c, d)
sequence from rMuV
JL5(F
JL2). (a) and (c) show
sequence electrochromatograms of the virion
sequence of the F polyadenylation region cut
to the first nucleotide difference between
MuV
JL2 and MuV
JL5 in the SH gene; (b) and
(d) show the 39-terminal region of the F mRNA
2. rMuV
JL2(F
JL5) has the F sequence char-
acteristic of rMuV
JL5 and the SH sequence
characteristic of rMuV
JL2, and rMuV
JL5(F
JL2)
has the F sequence characteristic of rMuV
JL2
and the SH sequence characteristic of
rMuV
JL5. The oligo-G insertion event in (d) is
indicated by a black bar and polyadenylation in
(b) and (d) by a dotted arrow.
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failure to terminate and polyadenylate. In addition, there
was sequence variation amongst our own six PCR-derived
clones from virion RNA of strain MuV
JL2 at this point –
one had a single addition to the six-adenosine tract,
another a single deletion from the seven-adenosine tract. It
was not clear, therefore, which motif would be used as the
polyadenylation signal during F gene mRNA synthesis for
strain MuV
JL2. The data showed clearly that termination
and polyadenylation of the F mRNA of MuV
JL2 occurs only
at the seven-adenosine tract, as in MuV
SBL, MuV
JL5 and
MuV
KH. During the study of the polyadenylation signals of
the F gene, an oligo-G insertion event was identified in the
39 non-coding region of the F gene of MuV
JL2 (and also in
rMuV
JL2). This leads to variable levels of insertion of a
number of additional G residues (one to seven, with a
mean of approximately four residues) at a site that directly
follows the six-adenosine tract and is similar in sequence to
a polyadenylation motif. The insertion of variable numbers
of G residues does not appear to affect the ability of the
virus to grow, and the motif appears only to be recognized
during transcription and not replication of the viral
genome. Exchanges of the F genes of rMuV
JL5 and
rMuV
JL2 showed clearly that the insertion of G residues
is a property of the sequence motif in the F gene of MuV
JL2
and not of the RdRp or the other genes of MuV
JL2,a si t
occurred in the F gene of MuV
JL2 placed in either the
rMuV
JL2 or the rMuV
JL5 background. However, the oligo-
G insertion into the F mRNA prior to polyadenylation was
not observed in MuV
KH, which also contains the same six-
and seven-adenosine tracts as MuV
JL2. MuV
JL2 has the
sequence GG at the oligo-G insertion site, whereas MuV
KH
has the sequence GA. This suggests that presence of a pair
of G residues between the two polyadenosine tracts is
necessary for the oligo-G insertion event to occur in
MuV
JL2. The oligo-G insertion at the 39 end of the MuV
JL2
F mRNA clearly resembles the viral RdRp slippage motif at
the P/V editing site (Elliott et al., 1990; Paterson & Lamb,
1990). At present, we do not know whether this oligo-G
insertion is a chance event that reflects the conjunction of
the pair of G residues between the six- and seven-adenosine
tracts so far restricted to MuV
JL2, or whether it has a
function. It may, for example, regulate transcription of the
SH gene by affecting transcription attenuation or the
formation of read-through products, which is a frequent
occurrence at this site (Afzal et al. 1990).
In conclusion, we have demonstrated significant sequence
variation and instability in the MuV
JL2 component of the
JL vaccine. In part, these sequence changes may be
generated by activity of cytosine and/or adenine deami-
nases in the cell. However, the inter-relationship of MuV
JL2
and MuV
JL5 is not clear and the sequence diversity even
between isolates of MuV
JL2 raises further questions about
the relationships between the two vaccine components. We
have developed a versatile rescue system for MuV based on
MuV
JL2 and used this and the MuV
JL5 rescue system to
prove that an oligo-G insertion event at the end of the F
gene of MuV
JL2 is determined by the sequence at the
slippage site.
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